Invesco Backs Delcath Systems (DCTH) on Expansion Potential

Delcath Systems, Inc. (NASDAQ:DCTH) is among the fastest growing small cap stocks to buy. Invesco Ltd. has expanded its position in Delcath Systems, Inc. (NASDAQ:DCTH) through the acquisition of 399,389 shares of the company’s stock, as revealed in the latest 13F filing with the Securities and Exchange Commission. With a transaction worth $5,084,000, the investment management firm now owns 1.19% of DCTH.

In the case of Delcath Systems, Inc. (NASDAQ:DCTH), its liver-directed chemotherapy system delivers meaningful clinical benefits; however, the market remains limited. What’s noteworthy is that the company is expanding into bigger cancer markets, and if successful, the company’s potential is enormous.

As Gerard J. Michel, the CEO, outlined,

“Preparations are underway to conduct company-sponsored trials in liver-dominant metastatic colorectal cancer and liver-dominant metastatic breast cancer, both of which allow us to approach large markets with clear unmet needs.”

Although Delcath Systems, Inc. (NASDAQ:DCTH) may face short-term challenges, such as pricing pressure from 340B/NDRA programs and high R&D costs, the company’s future growth depends on the success of its trials in metastatic breast and colorectal cancers. If things go as planned, the payoff could be massive.

Delcath Systems, Inc. (NASDAQ:DCTH) is a New York-based interventional oncology company that was founded in 1987. Through the revolution of the treatment of liver cancers, the company is committed to improving patient outcomes.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.